Ms Thomas believes the top 3 issues impacting pharmaceutical market access are:
"Maintenance of affordable high-quality health care; area of conflict between early adoption of innovation and valuing of true innovation; evidence-based health policy".
She is addressing the issues by:
"Objective examination of the advantages and disadvantages of medical services; production of independent, evidence-based reports e.g. on drugs."
Stefanie Thomas will be representing IQWiG at the Pharma Pricing & Market Access Outlook Europe 2012 which takes place in London next week. Here she will be elaborating on these issues. Other speakers include representatives from NICE, HAS, AHRQ, CVZ, PMPRB, NECA, CDE as well as industry input from GSK, Bristol-Myers Squibb, EFPIA, Novartis, Johnson & Johnson, Abbott and Roche.
Come to Pharma Pricing and Market Access Outlook Europe and learn:
- How the policy challenges in market access will effect you
- How to produce an optimum pricing strategy for your pharma products
- How HTA practice effects the markets you are working in
- How innovative pricing and risk sharing models between industry and payers have changed
Katie Barden
Marketing Director
Health Network Communications
Tel: 0207 608 7085